3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Urinary Bladder Neoplasms
8
Carcinoma, Merkel Cell
6
Neoplasm Metastasis
5
Carcinoma, Transitional Cell
5
Breast Neoplasms
5
Carcinoma, Renal Cell
4
Triple Negative Breast Neoplasms
2
Skin Neoplasms
2
Prostatic Neoplasms
2
Ovarian Neoplasms
2
Neuroendocrine Tumors
2
Melanoma
2
Carcinoma, Non-Small-Cell Lung
2
Uveal Melanoma
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Thymoma
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Primary Myelofibrosis
1
Penile Squamous Cell Carcinoma (PSCC)
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Neoplasms
1
Neoplasm, Residual
1
Muscle Invasive Bladder Urothelial Carcinoma
1
Metastatic Urothelial Cancer
1
Mesothelioma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Follicular
1
Interventions
Fluorouracil
13
pembrolizumab
12
Paclitaxel
12
Oxaliplatin
12
Leucovorin
9
Carboplatin
9
Capecitabine
8
Trastuzumab
7
Nivolumab
7
Cisplatin
7
Radiotherapy
6
Radiation
6
Taxes
5
Esophagectomy
5
Drug Therapy
5
Surgical Procedures, Operative
4
Specimen Handling
4
Irinotecan
4
trastuzumab deruxtecan
3
tislelizumab
3
patritumab deruxtecan
3
Radiotherapy, Intensity-Modulated
3
Proton Therapy
3
Immunotherapy
3
zanidatamab
2
ulixertinib
2
trastuzumab biosimilar HLX02
2
relatlimab
2
durvalumab
2
atezolizumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Esophageal Neoplasms
×
avelumab
×
90 days
×
Clear all
No trials found.